Showing results (11-20 of 58) with videos related to

Sort By:
Pageof 6
Drug Discovery Today|June 23, 2020
Exportin 1 inhibition as antiviral therapyMd Hafiz Uddin, Jeffrey A Zonder, Asfar S Azmi
Expert Opinion on Drug Discovery|December 6, 2016
The preclinical discovery and development of bortezomib for the treatment of mantle cell lymphomaRichard Arkwright, Tri Minh Pham, Jeffrey A Zonder, et al.
Oncology and Therapy|March 7, 2017
Phase I Study of Anti-GM2 Ganglioside Monoclonal Antibody BIW-8962 as Monotherapy in Patients with Previously Treated Multiple MyelomaRachid C Baz, Jeffrey A Zonder, Cristina Gasparetto, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 11, 2003
The effect of dose increase of imatinib mesylate in patients with chronic or accelerated phase chronic myelogenous leukemia with inadequate hematologic or cytogenetic response to initial treatmentJeffrey A Zonder, Pamela Pemberton, Helen Brandt, et al.
Molecular Cancer|November 19, 2021
Circular RNAs in acute myeloid leukemiaVijendra Singh, Mohammed Hafiz Uddin, Jeffrey A Zonder, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 24, 2009
Phase II study of thalidomide plus dexamethasone induction followed by tandem melphalan-based autotransplantation and thalidomide-plus-prednisone maintenance for untreated multiple myeloma: a southwest oncology group trial (S0204)Mohamad A Hussein, Vanessa Bolejack, Jeffrey A Zonder, et al.
Haematologica|November 30, 2023
Real-world multiple myeloma risk factors and outcomes by non-Hispanic Black/African American and non- Hispanic White race/ethnicity in the United StatesTondre Buck, Monique A Hartley-Brown, Yvonne A Efebera, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 22, 2020
Bendamustine With Dexamethasone in Relapsed/Refractory Systemic Light-Chain Amyloidosis: Results of a Phase II StudySuzanne Lentzsch, Galina G Lagos, Raymond L Comenzo, et al.
Cancer Medicine|June 11, 2014
A phase II trial of BAY 43-9006 (sorafenib) (NSC-724772) in patients with relapsing and resistant multiple myeloma: SWOG S0434Gordan Srkalovic, Mohamad A Hussein, Antje Hoering, et al.
Blood|September 30, 2010
Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232)Jeffrey A Zonder, John Crowley, Mohamad A Hussein, et al.
Pageof 6